Abstract B106: Algorithmic basis for combination of PI3K pathway isoform-specific inhibitors: Navigating the genomic landscape in ER+ breast cancers
Nandini Dey(University of South Dakota), Brian Leyland‐Jones(Avera Health), Casey Williams(Creighton University), Kirstin Williams(Avera Health), Amy Krie(Amgen (United States)), Jennifer Carlson(Avera Health), Pradip De(Avera Health), Jessica Klein(Cancer Institute (WIA))
Cited by 0
Related Papers
Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA
|Annals of Oncology|2020|1.5k
Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT study
|Nature Medicine|2019|726
RET rearrangements are actionable alterations in breast cancer
|Nature Communications|2018|127